Understanding Insomnia: Types and Evidence-Based Options
Last reviewed: March 21, 2026, 7:02 a.m.
Insomnia is the most common sleep disorder, affecting approximately 30% of adults occasionally and 10% on a chronic basis. It is defined not just by difficulty sleeping but by the daytime consequences that result, including fatigue, impaired concentration, mood disturbance, and reduced quality of life. Understanding the type and underlying contributors to your insomnia is essential for selecting appropriate interventions, whether behavioral, supplemental, or pharmaceutical.
Sleep-onset insomnia, characterized by difficulty falling asleep within 20 to 30 minutes, is often associated with hyperarousal, racing thoughts, or circadian misalignment. For this type, supplements that support relaxation and signal the body that it is time to sleep tend to be most relevant. Melatonin, taken at low doses (0.3-1 mg) 30 to 60 minutes before bed, may support circadian-mediated sleep onset. L-theanine (200-400 mg) promotes alpha brain wave activity and may reduce the anxious arousal that keeps the mind active at bedtime. GABA supplements, while having limited ability to cross the blood-brain barrier, may still exert peripheral effects that support relaxation in some individuals.
Sleep-maintenance insomnia, involving frequent awakenings during the night or difficulty returning to sleep after waking, has different underlying mechanisms. Common contributors include sleep apnea, restless leg syndrome, nocturia, chronic pain, hormonal changes (particularly during menopause), and anxiety. Magnesium glycinate may support sleep continuity through its effects on GABA receptors and nervous system regulation. Valerian root has traditionally been used for this purpose, with some studies showing improvements in sleep quality and reduced nighttime awakenings, though results are inconsistent across studies.
It is important to distinguish between supplement-responsive insomnia and insomnia that requires professional evaluation. Red flags that warrant medical consultation include snoring with witnessed breathing pauses (suggesting sleep apnea), irresistible urge to move the legs (restless leg syndrome), insomnia lasting more than 3 months, insomnia associated with significant daytime impairment, and insomnia occurring alongside symptoms of depression or anxiety. Cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment for chronic insomnia by the American Academy of Sleep Medicine and has demonstrated efficacy superior to sleep medications in long-term outcomes.
When considering supplements for insomnia, be cautious about products marketed with strong claims. No supplement can replace good sleep hygiene, and the most effective approach is typically a combination of behavioral changes, environmental optimization, and targeted supplementation. CBD has received significant attention for sleep, though research is still in early stages and regulatory quality control varies widely between products. Start with well-studied supplements at established doses, give each a fair trial of 2 to 4 weeks, and keep a sleep diary to objectively track whether the supplement is making a measurable difference.
Sleep-onset insomnia, characterized by difficulty falling asleep within 20 to 30 minutes, is often associated with hyperarousal, racing thoughts, or circadian misalignment. For this type, supplements that support relaxation and signal the body that it is time to sleep tend to be most relevant. Melatonin, taken at low doses (0.3-1 mg) 30 to 60 minutes before bed, may support circadian-mediated sleep onset. L-theanine (200-400 mg) promotes alpha brain wave activity and may reduce the anxious arousal that keeps the mind active at bedtime. GABA supplements, while having limited ability to cross the blood-brain barrier, may still exert peripheral effects that support relaxation in some individuals.
Sleep-maintenance insomnia, involving frequent awakenings during the night or difficulty returning to sleep after waking, has different underlying mechanisms. Common contributors include sleep apnea, restless leg syndrome, nocturia, chronic pain, hormonal changes (particularly during menopause), and anxiety. Magnesium glycinate may support sleep continuity through its effects on GABA receptors and nervous system regulation. Valerian root has traditionally been used for this purpose, with some studies showing improvements in sleep quality and reduced nighttime awakenings, though results are inconsistent across studies.
It is important to distinguish between supplement-responsive insomnia and insomnia that requires professional evaluation. Red flags that warrant medical consultation include snoring with witnessed breathing pauses (suggesting sleep apnea), irresistible urge to move the legs (restless leg syndrome), insomnia lasting more than 3 months, insomnia associated with significant daytime impairment, and insomnia occurring alongside symptoms of depression or anxiety. Cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment for chronic insomnia by the American Academy of Sleep Medicine and has demonstrated efficacy superior to sleep medications in long-term outcomes.
When considering supplements for insomnia, be cautious about products marketed with strong claims. No supplement can replace good sleep hygiene, and the most effective approach is typically a combination of behavioral changes, environmental optimization, and targeted supplementation. CBD has received significant attention for sleep, though research is still in early stages and regulatory quality control varies widely between products. Start with well-studied supplements at established doses, give each a fair trial of 2 to 4 weeks, and keep a sleep diary to objectively track whether the supplement is making a measurable difference.